These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12473657)

  • 1. A two-drug model for etoposide action against human topoisomerase IIalpha.
    Bromberg KD; Burgin AB; Osheroff N
    J Biol Chem; 2003 Feb; 278(9):7406-12. PubMed ID: 12473657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage.
    Bromberg KD; Burgin AB; Osheroff N
    Biochemistry; 2003 Apr; 42(12):3393-8. PubMed ID: 12653542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-Mechanism Model for the Interaction of Etoposide Quinone with Topoisomerase IIα.
    Gibson EG; King MM; Mercer SL; Deweese JE
    Chem Res Toxicol; 2016 Sep; 29(9):1541-8. PubMed ID: 27533850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contributions of the D-Ring to the activity of etoposide against human topoisomerase IIα: potential interactions with DNA in the ternary enzyme--drug--DNA complex.
    Pitts SL; Jablonksy MJ; Duca M; Dauzonne D; Monneret C; Arimondo PB; Anklin C; Graves DE; Osheroff N
    Biochemistry; 2011 Jun; 50(22):5058-66. PubMed ID: 21548574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
    Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
    Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences.
    Infante Lara L; Fenner S; Ratcliffe S; Isidro-Llobet A; Hann M; Bax B; Osheroff N
    Nucleic Acids Res; 2018 Mar; 46(5):2218-2233. PubMed ID: 29447373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using 3'-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase IIalpha.
    Deweese JE; Burgin AB; Osheroff N
    Biochemistry; 2008 Apr; 47(13):4129-40. PubMed ID: 18318502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.
    Byl JA; Cline SD; Utsugi T; Kobunai T; Yamada Y; Osheroff N
    Biochemistry; 2001 Jan; 40(3):712-8. PubMed ID: 11170388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coordinating the two protomer active sites of human topoisomerase IIalpha: nicks as topoisomerase II poisons.
    Deweese JE; Osheroff N
    Biochemistry; 2009 Feb; 48(7):1439-41. PubMed ID: 19166355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HU-331 is a catalytic inhibitor of topoisomerase IIα.
    Regal KM; Mercer SL; Deweese JE
    Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity.
    Bender RP; Jablonksy MJ; Shadid M; Romaine I; Dunlap N; Anklin C; Graves DE; Osheroff N
    Biochemistry; 2008 Apr; 47(15):4501-9. PubMed ID: 18355043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme.
    Dickey JS; Osheroff N
    Biochemistry; 2005 Aug; 44(34):11546-54. PubMed ID: 16114891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase IIα and IIβ.
    Oviatt AA; Kuriappan JA; Minniti E; Vann KR; Onuorah P; Minarini A; De Vivo M; Osheroff N
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2961-2968. PubMed ID: 30006062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
    Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
    Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoposide, topoisomerase II and cancer.
    Baldwin EL; Osheroff N
    Curr Med Chem Anticancer Agents; 2005 Jul; 5(4):363-72. PubMed ID: 16101488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage.
    Fortune JM; Osheroff N
    J Biol Chem; 1998 Jul; 273(28):17643-50. PubMed ID: 9651360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation of cysteine residue 455 to alanine in human topoisomerase IIalpha confers hypersensitivity to quinones: enhancing DNA scission by closing the N-terminal protein gate.
    Bender RP; Osheroff N
    Chem Res Toxicol; 2007 Jun; 20(6):975-81. PubMed ID: 17516663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.